December 7, 2017, Shanghai, Boston, Hong Kong, San Francisco. 6 Dimensions Capital announces today the final close of its inaugural US dollar fund & RMB fund at US$533 million and RMB2.06 billion respectively, both exceeded the original US$450 million and RMB1.5 billion target. Formed through a merger between Frontline BioVentures and WuXi Healthcare Ventures in May 2017, 6 Dimensions Capital has established itself firmly as one of the largest healthcare focused investment firms with coverage across China and the U.S. Investors in the USD fund include some of the prominent industry leaders along with endowments, foundations, and sovereign wealth funds, and investors in the RMB fund include some of the top-tier fund-of-funds, mainstream insurance companies, and industrial leading players. Commenting on the successful fund raising over a short six-month period, Dr. Leon Chen, Founding Partner & CEO of 6 Dimensions Capital, stated proudly, “I am grateful for the trust and support from many high-caliber investors, who recognize our proven abilities to create values through game changing investment practice. We have a capable professional team with cross-border coverage in the life sciences arena and we have the aspiration to foster the established ecosystem to identify innovations, build platform companies and help entrepreneurs transform their dreams to successful businesses.” Dr. Ge Li, Founding Partner & Chairman of 6 Dimensions Capital, noted, “I am very pleased to see the enthusiasm from the investment community that embraces healthcare opportunities as much as we do. I believe this significant amount of fresh capital will empower the 6 Dimensions Capital team to execute our highly differentiated investment strategies and solidify our leadership in the healthcare venture investment.” 
News | 6 Dimensions Capital Closed Oversubscribed 1st USD Fund and RMB Fund, Bringing Total AUM Over RMB 10Bn (USD 1.5Bn)